- Home
- SRZN vs IAF Comparison
SRZN vs IAF Comparison
Compare SRZN & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- IAF
- Stock Information
- Founded
- SRZN 2015
- IAF 1985
- Country
- SRZN United States
- IAF United States
- Employees
- SRZN N/A
- IAF N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- IAF Finance/Investors Services
- Sector
- SRZN Health Care
- IAF Finance
- Exchange
- SRZN Nasdaq
- IAF Nasdaq
- Market Cap
- SRZN 117.8M
- IAF 123.6M
- IPO Year
- SRZN N/A
- IAF N/A
- Fundamental
- Price
- SRZN $13.23
- IAF $12.43
- Analyst Decision
- SRZN Strong Buy
- IAF
- Analyst Count
- SRZN 2
- IAF 0
- Target Price
- SRZN $38.50
- IAF N/A
- AVG Volume (30 Days)
- SRZN 92.5K
- IAF 90.4K
- Earning Date
- SRZN 11-07-2025
- IAF 01-01-0001
- Dividend Yield
- SRZN N/A
- IAF 11.44%
- EPS Growth
- SRZN N/A
- IAF N/A
- EPS
- SRZN N/A
- IAF N/A
- Revenue
- SRZN $3,604,000.00
- IAF N/A
- Revenue This Year
- SRZN N/A
- IAF N/A
- Revenue Next Year
- SRZN N/A
- IAF N/A
- P/E Ratio
- SRZN N/A
- IAF N/A
- Revenue Growth
- SRZN N/A
- IAF N/A
- 52 Week Low
- SRZN $5.90
- IAF $3.60
- 52 Week High
- SRZN $18.17
- IAF $4.59
- Technical
- Relative Strength Index (RSI)
- SRZN 51.18
- IAF 64.17
- Support Level
- SRZN $12.12
- IAF $12.26
- Resistance Level
- SRZN $14.18
- IAF $13.00
- Average True Range (ATR)
- SRZN 0.75
- IAF 0.22
- MACD
- SRZN 0.06
- IAF -0.43
- Stochastic Oscillator
- SRZN 61.92
- IAF 14.08
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.